Publications by authors named "Amanda Copeland"

Claim this Profile
E
Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study.
Philani Mpofu, Seamus Kent, Páll Jónsson, Harlan Pittell, Brad Groves, Amanda Copeland

BMJ Open· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma.
Jacob D Soumerai, Andy Ni, Anna Alperovich, Connie Batlevi, Kurt S Bantilan, Amanda R Copeland

Leuk Lymphoma· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Brentuximab Vedotin: A Nursing Perspective on Best Practices and Management of Associated Adverse Events.
Kathleen Clifford, Amanda Copeland, Gregory Knutzen, Ellen Samuelson, Laurie Grove

Clin J Oncol Nurs· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.
Andrew M Intlekofer, Erel Joffe, Connie L Batlevi, Patrick Hilden, Jie He, Amanda R Copeland

Blood Cancer J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.
Bei Hu, Anas Younes, Jason R Westin, Francesco Turturro, Linda Claret, Amanda R Copeland

Leuk Lymphoma· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma.
Connie L Batlevi, Michael Crump, Charalambos Andreadis, David Rizzieri, Sarit E Assouline, Amanda Copeland

Br J Haematol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.
Connie Lee Batlevi, Yvette Kasamon, R Gregory Bociek, Peter Lee, Lia Gore, Amanda Copeland

Haematologica· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Anas Younes, Jesus G Berdeja, Manish R Patel, Ian Flinn, John F Gerecitano, Amanda R Copeland

Lancet Oncol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma.
Yasuhiro Oki, Michelle Fanale, Jorge Romaguera, Luis Fayad, Nathan Fowler, Amanda Copeland

Br J Haematol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma.
Yasuhiro Oki, Daniela Buglio, Michelle Fanale, Luis Fayad, Amanda Copeland

Clin Cancer Res· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma.
Yasuhiro Oki, Anas Younes, Amanda Copeland, Fredrick Hagemeister, Luis E Fayad

Br J Haematol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes.
Anas Younes, Jorge Romaguera, Michelle Fanale, Peter McLaughlin, Frederick Hagemeister, Amanda Copeland

J Clin Oncol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Current treatment strategies in Hodgkin lymphomas.
Amanda Copeland, Anas Younes

Curr Opin Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma.
Anas Younes, Stella Kim, Jorge Romaguera, Amanda Copeland, Silvana de Castro Farial

J Clin Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma.
Yasuhiro Oki, Amanda Copeland, Jorge Romaguera, Luis Fayad, Michelle Fanale

Leuk Lymphoma· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study.
Nicolas Batty, Fredrick B Hagemeister, Lei Feng, Jorge E Romaguera, Maria A Rodriguez, Amanda Copeland

Leuk Lymphoma· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma.
Anas Younes, Yasuhiro Oki, Peter McLaughlin, Amanda R Copeland, Andre Goy

Blood· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Experience with obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with relapsed or refractory classical Hodgkin lymphoma.
Yasuhiro Oki, Amanda Copeland, Fredrick Hagemeister, Luis E Fayad, Michelle Fanale

Blood· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial.
Anas Younes, Yasuhiro Oki, R Gregory Bociek, John Kuruvilla, Michelle Fanale, Amanda Copeland

Lancet Oncol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4.
Conrad R Cruz, Ulrike Gerdemann, Ann M Leen, Jessica A Shafer, Stephanie Ku, Amanda Copeland

Clin Cancer Res· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of panobinostat in classical Hodgkin's lymphoma.
Yasuhiro Oki, Amanda Copeland, Anas Younes

Expert Rev Hematol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Histone deacetylase inhibitors in lymphoma.
Amanda Copeland, Daniela Buglio, Anas Younes

Curr Opin Oncol· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
Michael Wang, Yasuhiro Oki, Barbara Pro, Jorge Enrique Romaguera, Maria Alma Rodriguez, Amanda Copeland

J Clin Oncol· November 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis